Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Twitter summary: Due to company misconduct by Andromeda, biotech co. Hyperion terminates development of immune intervention therapy for #T1D On September 8, Hyperion...
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
Twitter Summary: @DpT1D of the #helmsleytrust talks about need 4 philanthropic support in #T1D in inspiring Wired op-ed David Panzirer , a trustee of the Helmsley...
Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
On September 24, JAMA published a paper on long-term trends in the number of people with diabetes in the United States from 1980 to 2012. The results showed a leveling-...
Advances for type 2 diabetes at The American Diabetes Association 74th Scientific Sessions
Twitter summary: A new technology from Stanford has potential for easier, more accurate, & cheaper diagnosis for #t1d A team of Stanford University researchers, with...
The T1D Exchange: a bold vision to advance the field of type 1 diabetes – part four of our interview with David Panzirer and Dana Ball.
The hope and hype of curing diabetes with stem cells – our take on the Harvard research and more.
Why aren’t there more therapies and devices for pediatric patients? Find out why and what we can do to help.
Can artificial sweeteners contribute to weight gain and worse diabetes control? A remarkable new study on the role of gut bacteria...
We sit down with new JDRF CEO Derek Rapp for his first interview as CEO – find out what he's excited about for JDRF's future!
Twitter Summary: ViaCyte seeks approval from FDA for first human studies of novel encapsulation stem-cell therapy for #t1D On July 17, ViaCyte filed applications with...
Twitter summary: Using a #T2D therapy for #T1D, Lexicon & JDRF partner up for phase 2 trial of SGLT-2/SGLT-1 dual inhibitor drug On July 9, Lexicon announced a...
Starting in 2012, the American Diabetes Association established the Pathway to Stop Diabetes initiative, a $1.6 million grant (paid over five years) to support the...
What’s next for getting this software to patients?
Kicking off this weekend, what are we most excited about for this year’s ADA?
How these two FDA-submitted drugs could address this major healthcare need.
Dr. Kowalski was recently named JDRF’s Chief Mission Officer as well as VP of R&D, a major promotion from his previous role as Vice President, Artificial Pancreas...
There was a lot of interest this ADA in the Harvard Stem Cell Institute's diabetes research (not yet in humans), which has previously shown the ability to produce mature...

Pages